Dr. Jun Bao, Senior Vice President & Chief Business Officer of Shenogen Pharma Group, will attend 2014 US / China "Bridge" Business Development Summit on behalf of Shenogen.  The Summit is organized by Vivo Capital on March 7th 2014 in Shanghai.

About Shenogen

Shenogen Pharma Group is a drug discovery and development company based in Beijing, China that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.